Title: Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-
associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
Version: 3 Date: 19 Jun 2023
Reviewer:  Tajana Filipec Kanizaj
Reviewer's report:
The paper represents cross-sectional study evaluating the performances of MAFLD screening
score (MAFLD-S), Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI) and Clinical
Prediction Tool for NAFLD in Crohn’s Disease (CPN-CD) for identifying the presence of
MAFLD in IBD patients.
The authors showed a high prevalence of MAFLD in the IBD population implying either specific
pathogenetic mechanisms associated with IBD or a higher prevalence of MeS components in
this population? Which of the proposed mechanisms do the authors consider more relevant?
Although conventional NITs have proven to be effective in this population as well, do the authors
think that there should be specific tests for this population that include the specificities of IBD?
Bearing in mind the specifics of nutritional support in the treatment of IBD, do the authors
think that screening for MAFLD in the IBD population can have clinical consequences for the
treatment of IBD patients?
Do the authors have knowledge about presence of liver biopsy findings in these patients or non-
invasive tests were only ones performed?
The title, abstract, manuscript organization, discussion, tables, figures and references are
appropriate.
Language requires significant polishing to achieve precision, clarity and grammatical
correctness.
Title: Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-
associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
Version: 3 Date: 19 Jun 2023
Reviewer:  Tajana Filipec Kanizaj
Reviewer's report:
The paper represents cross-sectional study evaluating the performances of MAFLD screening
score (MAFLD-S), Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI) and Clinical
Prediction Tool for NAFLD in Crohn’s Disease (CPN-CD) for identifying the presence of
MAFLD in IBD patients.
The authors showed a high prevalence of MAFLD in the IBD population implying either specific
pathogenetic mechanisms associated with IBD or a higher prevalence of MeS components in
this population? Which of the proposed mechanisms do the authors consider more relevant?
Although conventional NITs have proven to be effective in this population as well, do the authors
think that there should be specific tests for this population that include the specificities of IBD?
Bearing in mind the specifics of nutritional support in the treatment of IBD, do the authors
think that screening for MAFLD in the IBD population can have clinical consequences for the
treatment of IBD patients?
Do the authors have knowledge about presence of liver biopsy findings in these patients or non-
invasive tests were only ones performed?
The title, abstract, manuscript organization, discussion, tables, figures and references are
appropriate.
Language requires significant polishing to achieve precision, clarity and grammatical
correctness.
Please review this paper.
user
Title: Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-
associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
Version: 3 Date: 19 Jun 2023
Reviewer:  Tajana Filipec Kanizaj
Reviewer's report:
The paper represents cross-sectional study evaluating the performances of MAFLD screening
score (MAFLD-S), Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI) and Clinical
Prediction Tool for NAFLD in Crohn’s Disease (CPN-CD) for identifying the presence of
MAFLD in IBD patients.
The authors showed a high prevalence of MAFLD in the IBD population implying either specific
pathogenetic mechanisms associated with IBD or a higher prevalence of MeS components in
this population? Which of the proposed mechanisms do the authors consider more relevant?
Although conventional NITs have proven to be effective in this population as well, do the authors
think that there should be specific tests for this population that include the specificities of IBD?
Bearing in mind the specifics of nutritional support in the treatment of IBD, do the authors
think that screening for MAFLD in the IBD population can have clinical consequences for the
treatment of IBD patients?
Do the authors have knowledge about presence of liver biopsy findings in these patients or non-
invasive tests were only ones performed?
The title, abstract, manuscript organization, discussion, tables, figures and references are
appropriate.
Language requires significant polishing to achieve precision, clarity and grammatical
correctness.
assistant